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ABSTRACT
The therapeutic options for disease modification
in relapsing-remitting multiple sclerosis (RRMS)
have expanded remarkably in the last 15 years.
Although intravenous immunoglobulins (IVIg)
have shown some therapeutic effects in multiple
sclerosis, reducing global supplies, restriction of
treatment to essential indications and availability
of effective alternative treatments forMScurrently
exclude IVIg from being an accepted therapy for
MS, other than for some exceptional considera-
tions. We report the case of a female patient with
RRMS who was diagnosed with Ehlers-Danlos
syndrome (EDS) and Muir-Torre syndrome (MTS)
soon after the diagnosis of active RRMSwasmade.
The coexisting conditions precluded the use of
available disease-modifying treatments. She ben-
efited from monthly and then bi-monthly IVIg,
with a single mild relapse over 10 years. Discon-
tinuationof IVIg due to reduced availabilitywitha
brief aborted course of subcutaneous PEGylated
interferon-beta was followed by significant relap-
ses. Five months after the first ocrelizumab infu-
sion, she developed caecal cancer requiring
colectomy. Reinstitution of IVIg is contemplated.
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Key Summary Points
A complex case of RRMS with EDS and
MTS-probable association/trigger/
unmasking
IVIg has been found beneficial as an
immunomodulatory and potential cancer
immunoprophylaxis agent
Unmet need of treatment options in this
rare case—IVIg kept MS and cancer in
remission
Despite the global shortage of IVIg, it
should be considered for clinically
indicated cases
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INTRODUCTION
The landscape for disease-modifying treatments
for multiple sclerosis (MS), in particular for the
relapsing-remitting forms, has changed dra-
matically over the last two decades. All current
treatments target the immune system by
reducing pro-inflammatory responses, blocking
lymphocyte migration, providing non-specific
immunosuppression or depleting selected
immune cell populations.
Despite the evidence of a potential thera-
peutic benefit, intravenous immunoglobulin
(IVIg) is currently only very rarely used in MS,
where it is reserved for special situations, for
example in the post-partum period to prevent
post-partum relapses [1]. However, as resump-
tion of disease-modifying treatments in the
immediate post-partum period is increasingly
accepted, IVIg use has declined even for this
indication.
Secondary antibody deficiencies are increas-
ingly diagnosed during the course of B cell-de-
pleting therapies for central nervous
inflammatory conditions, but these are typi-
cally seen with neuromyelitis optica spectrum
disorders under rituximab treatment. Some of
the affected patients benefit from IVIg given as
prophylaxis against recurrent infections [2].
A major consideration in restricting the use
of IVIg to conditions where alternatives are
lacking is the declining supply of
immunoglobulin worldwide, related to a
reducing number of donors. This further
excludes MS as an indication for IVIg other than
for exceptional cases.
We report a unique case of a patient with
relapsing-remitting multiple sclerosis (RRMS)
whose constellation of co-morbidities (which
included predisposition to cancer) precluded
the use of the other available disease-modifying
treatments. She benefited from monthly and
then bi-monthly IVIg, with a single MS relapse
and no recurrence of cancer in[10 years.
CASE REPORT
A 67-year old woman had optic neuritis at age
46 and was diagnosed with RRMS 1 year later.
She had three clinical relapses requiring corti-
costeroid treatment in the first 18 months of
the disease. A short course of subcutaneous
interferon beta 1a (Rebif) was discontinued
because of side effects (mood changes and sev-
ere bruising at the injection sites).
Three years after the first symptoms, she was
recruited into a randomized placebo-controlled
clinical trial of anti-IL-12 antibody for RRMS [3].
As part of the screening for the trial, a past
personal and strong family history of hyper-
mobility, increased skin elasticity and frequent
joint dislocations was elicited, leading to the
diagnosis of hypermobile Ehlers-Danlos syn-
drome (EDS), possibly with additional features
(e.g., vascular fragility). Further family history
was notable for endometrial adenocarcinoma in
her mother and sister.
During the trial, she remained stable neuro-
logically. Towards the end of the trial she
developed a skin lesion on the left shoulder,
which was biopsied and diagnosed as sebaceous
adenoma.
This diagnosis taken together with her
family history of endometrial cancer raised
concerns about a diagnosis of Muir-Torre syn-
drome (MTS), which is a variant/subtype of
Lynch syndrome [4]. Genetic testing showed
that she was heterozygous for a constitutional
pathogenic nonsense variant (p.(Lys537Ter) in
the MSH2 gene. Screening for Lynch syn-
drome-related visceral malignancies was com-
menced. Soon after the end of the trial, where
she had been allocated to the treatment arm
(anti-IL-12 antibody), she was assessed for and
confirmed as having endometrial carcinoma
and hospitalized for hysterectomy and bilat-
eral salpingo-oophorectomy. She suffered
massive bleeding with hypovolemic shock
during surgery. Excessive vascular fragility
attributed to her EDS was noted during the
surgery. After two severe MS relapses within
6 months, therapeutic choices were considered
in multidisciplinary discussions. Beta-inter-
feron and glatiramer acetate were avoided
because of severe bruising with frequent
injections. Immunosuppressants and natal-
izumab were ruled out in view of increased
risk of MTS-associated malignancies during
immunosuppression [5].
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IVIg was considered the safest option, and
the treatment was approved by the hospital’s
IVIg panel committee.
Due to vein fragility, a porta-cath was placed,
and she was started on IVIg, 0.4 g/kg, one
infusion every month for the first 2 years and
then every 2 months subsequently. She had no
further relapses for 3.5 years while being on IVIg
except a short episode of oscillopsia lasting
about 3 weeks, which resolved spontaneously.
The MRI scan of the brain at that time did not
show any new or acute lesions. She continued
on IVIg with no relapses, no side effects and
minimal disease progression (0.5 EDSS step) for
a further 7 years. The frequency of UTI dropped
to almost none during the IVIg treatment. She
underwent routine periodic screening for
malignancies throughout this period and did
not develop new malignancy indicating the
potential role of IVIg as an anti-cancer therapy
[6, 7].
After 10 years, because of the global short-
age of IVIg, the treatment was discontinued.
After some deliberations, the patient agreed to
start the fortnightly preparation of pegylated
interferon beta 1-a (Plegridy) in view of the
low frequency of administration. After perse-
vering for 6 months despite bruising at the
injection site and low mood, she had
increased suicidal ideation and hence stopped
the interferon treatment. Two months later,
she had a severe relapse with paraplegia
requiring hospitalization and intravenous
steroids. After her recovery, ocrelizumab, a B
cell-depleting agent, was initiated. Five
months after the first infusion, she was diag-
nosed with caecal carcinoma during a routine
surveillance colonoscopy.
She underwent colectomy (with extensive
precautions to prevent bleeding) with a stoma
placement. In the post-operative period, she
experienced a further significant relapse pre-
senting with severe weakness and cerebellar
dysfunction. She is currently rehabilitating,
though not completely returned to her preop-
erative baseline. A reinstitution of IVIg has been
requested and awaits approval.
DISCUSSION
We report a unique case of a patient with active
RRMS who experienced significant relapses off
treatment that were all but abolished during
treatment with IVIg. In this case we had no
choice but to give IVIg because of her coexisting
conditions barring her from regular
injectable drugs and immunosuppressive
treatment.
Due to the increasing number and efficacy of
therapeutic agents for MS, in addition to the
global shortage, IVIg is no longer advocated as a
treatment for MS. However, aside from these
considerations, the body of evidence for IVIg is
substantial. A meta-analysis by Sorensen et al.
[8] combined four studies to assess the efficacy
of IVIg in RRMS in a randomized, placebo-con-
trolled manner. The study showed a significant
beneficial effect on the annual relapse rate (ef-
fect size - 0.5; P = 0.00003) on the proportion
of relapse-free patients (0.29 difference;
P = 2.1 9 10–8), change in the Expanded Dis-
ability Status Scale (EDSS) (effect size: 0.25;
P = 0.04) and a trend towards a reduction in the
proportion of patients who deteriorated
(P = 0.03). Each single study in the meta-anal-
ysis had its weaknesses, but all studies were
positive regarding their primary end point, and
the results yield concordant evidence for
reduction of the relapse rate and progression
[8].
Another meta-analysis by Olayeemanesh
et al. [9] combined six studies using a parallel-
group design. The pooled results revealed sig-
nificant differences in the number of relapses
experienced on an annual basis in favour of IVIg
(SMD = - 0.218; 95% CI - 0.412 to - 0.024;
P = 0.028) [9].
Ehlers-Danlos syndrome is not commonly
associated with neurological manifestations.
The most common are vascular features, such as
aneurysm, subarachnoid haemorrhage and
spontaneous arterial dissection. Various con-
genital malformations of the vessels and the
brain parenchyma have been reported along
with symptomatic and idiopathic epilepsy
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[10, 11]. Our case series of four patients with MS
and EDS showed joint laxity as the most
prominent feature [12]. There have been case
reports of EDS and leukodystrophy [13]. Extra-
cellular matrix (ECM) proteins play an impor-
tant role in CNS inflammation and
myelination, endothelial lining, binding of
soluble cytokines and adhesion of inflammatory
cells, cellular migration and organization [14].
There is a suspicion that abnormalities in ECM
protein can increase the susceptibility to
autoimmune conditions [15]. Health care pro-
fessionals need to be aware of several manage-
ment issues in patients with MS and EDS such as
increased risk of joint dislocation or arterial
dissection during active physiotherapy [12].
Also, in this case due to EDS the skin can be
very fragile and easily bruised, which would
make any vascular access difficult. The patient
was deemed unsuitable for subcutaneous
injectable disease-modifying treatment because
of skin fragility. Notably, there is a case series of
two patients who had hypermobile EDS and
MS/NMOSD-like CNS manifestations that were
responsive to corticosteroids and plasmaphere-
sis treatment. The authors found paraplegia
more reversible in this category of patients
compared to MS/NMOSD following
immunotherapy [16].
Muir-Torre syndrome (MTS), an autosomal
dominant condition caused by mutations in the
mismatch repair genes, often MSH2, is part of
the spectrum of Lynch syndrome (formerly
called hereditary nonpolyposis colorectal can-
cer) that in addition presents sebaceous tumors
including sebaceous adenoma. The onset of
these tumors has been shown to be triggered or
unmasked by immunocompromised states,
either through pharmacological immunosup-
pression or through acquired immunodefi-
ciency [5, 17, 18]. Once such a tumor is
diagnosed, screening for visceral malignancies
(colorectal and genito-urinary) and suspicion of
MTS is essential. Avoidance of immunosup-
pressive therapies is also important.
An argument has been made for imple-
menting immuno-interception using immune
checkpoint inhibitors in MTS, following a
report of a successful immuno-interception in a
patient with 136 cutaneous and visceral
tumours [19]. However, immune checkpoint
inhibitors have been associated with a number
of autoimmune neurological syndromes and
can cause severe, even fatal, exacerbations of MS
[20].
In our patient, it is tempting to speculate
that IVIg, in addition to its sustained and
thorough control of MS disease activity, may
have also provided effective immuno-intercep-
tion. The anti-tumor and anti-metastatic effect
of IVIg has been recognized, and the occurrence
of colon cancer after discontinuation of a
10-year-long course of IVIg may represent ces-
sation of immuno-interception, more likely
than an immunosuppressive effect of ocre-
lizumab, given that the patient only had one
course of this drug.
In conclusion, despite the restrictions in the
use of IVIg due to its globally reduced avail-
ability, this unique case illustrates a multitude
of beneficial effects that warrant its continued
use as a rare clinically indicated exception.
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